Equities research analysts expect Anterix Inc. (NASDAQ:ATEX – Get Rating) to announce sales of $520,000.00 for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Anterix’s earnings, with the highest sales estimate coming in at $800,000.00 and the lowest estimate coming in at $370,000.00. Anterix posted sales of $180,000.00 in the same quarter last year, which suggests a positive year over year growth rate of 188.9%. The company is expected to announce its next earnings report on Monday, January 1st.
According to Zacks, analysts expect that Anterix will report full year sales of $1.27 million for the current financial year, with estimates ranging from $1.12 million to $1.55 million. For the next year, analysts expect that the company will post sales of $5.78 million, with estimates ranging from $3.02 million to $7.60 million. Zacks’ sales calculations are an average based on a survey of analysts that that provide coverage for Anterix.
Anterix (NASDAQ:ATEX – Get Rating) last announced its earnings results on Thursday, February 3rd. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.03). The firm had revenue of $0.39 million during the quarter, compared to the consensus estimate of $0.42 million. Anterix had a negative return on equity of 22.93% and a negative net margin of 5,120.54%. During the same quarter last year, the business earned ($0.69) EPS.
ATEX traded down $0.29 during trading on Tuesday, hitting $56.65. The stock had a trading volume of 31,299 shares, compared to its average volume of 64,991. The company has a 50 day simple moving average of $56.23 and a 200-day simple moving average of $57.70. Anterix has a 12 month low of $45.11 and a 12 month high of $66.55. The firm has a market cap of $1.04 billion, a PE ratio of -21.38 and a beta of 0.46.
In other news, Chairman Morgan E. Obrien sold 25,000 shares of Anterix stock in a transaction dated Tuesday, March 15th. The shares were sold at an average price of $56.02, for a total transaction of $1,400,500.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 4.05% of the stock is currently owned by insiders.
Several institutional investors have recently modified their holdings of ATEX. Invesco Ltd. acquired a new stake in shares of Anterix during the 2nd quarter valued at about $237,000. Morgan Stanley boosted its position in Anterix by 6.1% in the second quarter. Morgan Stanley now owns 1,403,221 shares of the company’s stock valued at $84,179,000 after buying an additional 80,091 shares in the last quarter. Parametric Portfolio Associates LLC boosted its position in Anterix by 15.2% in the second quarter. Parametric Portfolio Associates LLC now owns 31,055 shares of the company’s stock valued at $1,863,000 after buying an additional 4,089 shares in the last quarter. Kirr Marbach & Co. LLC IN acquired a new position in Anterix in the third quarter valued at about $3,405,000. Finally, SG Americas Securities LLC acquired a new position in Anterix in the third quarter valued at about $1,405,000. Institutional investors and hedge funds own 82.93% of the company’s stock.
About Anterix (Get Rating)
Anterix Inc operates as a wireless communications company. The company focuses on commercializing its spectrum assets to enable the targeted utility and critical infrastructure customers to deploy private broadband networks, technologies, and solutions. It holds licensed spectrum in the 900 MHz band with nationwide coverage throughout the United States, Alaska, Hawaii, and Puerto Rico.
- Get a free copy of the StockNews.com research report on Anterix (ATEX)
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
- Top 3 Safe Stocks for Conservative Investors
- Array Technologies Stock Giving Another Ground Floor Entry
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Anterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anterix and related companies with MarketBeat.com's FREE daily email newsletter.